<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="3" ids="50249">Anticoagulant</z:chebi> therapy in the treatment of cerebral <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> remains controversial despite 20 years of statistical studies </plain></SENT>
<SENT sid="1" pm="."><plain>Among the unresolved questions are (1) the relative value of aspirin vs <z:chebi fb="2" ids="28794">coumarin</z:chebi> derivatives for long-term therapy; (2) the relative benefits of long-term therapy vs short-term therapy; (3) the complications of <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy vs their therapeutic benefits; and (4) the optimal therapy of the various types of cerebral <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo>, eg, <z:hpo ids='HP_0002326'>transient ischemic attacks</z:hpo>, <z:hpo ids='HP_0001297'>strokes</z:hpo> in evolution, and completed <z:hpo ids='HP_0001297'>strokes</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Much of this controversy derives from the same problems that have plagued the question of anticoagulation for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, namely that "the existing statistics were obtained without adequate attention to fundamental principles of clinical science" </plain></SENT>
<SENT sid="3" pm="."><plain>We have examined the available clinical studies bearing on this issue and are reporting our analysis of these studies </plain></SENT>
</text></document>